VANQUISH-1 and VANQUISH-2 Studies to Evaluate Subcutaneous VK2735 in Obese Adults with and without Type 2 Diabetes SAN DIEGO, June 25, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. (VKTX), a clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback